查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2024185

免疫腫瘤診斷市場：按檢測類型、技術、客戶和國家分類的預測—高階主管和顧問指南（2026-2030 年）—第四版

Immuno-Oncology Diagnostics. Market Forecasts for Immuno-Oncology Diagnostics by Assay Type, Technology, Client, and Country. With Executive/Consultant Guides. 2026 to 2030 (4th Edition)
出版日期: | 出版商: Howe Sound Research | 英文 479 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

市場概況：

2025年市場規模：62.2億美元；2030年市場規模：111億美元；複合年成長率：12.3%

免疫腫瘤學（IO）診斷是用於識別預測患者對免疫療法反應的生物標記的體外診斷測試。這些療法能夠刺激或恢復免疫系統識別和摧毀癌細胞的能力，是過去十年腫瘤學領域最重大的進展之一。隨著免疫療法逐漸成為多種腫瘤類型的標準治療方案，指導患者選擇的診斷測試正成為臨床決策中不可或缺的關鍵要素。

隨著免疫療法藥物類別的快速擴張，包括免疫查核點抑制劑、CAR-T細胞療法、雙特異性抗體和治療性癌症疫苗，免疫腫瘤診斷市場也同步發展。與專注於特定基因突變的傳統標靶治療不同，免疫療法依賴腫瘤與免疫系統之間的複雜相互作用。因此，免疫腫瘤診斷通常需要評估多種生物學參數，例如蛋白質表現、免疫細胞浸潤、腫瘤突變負荷和基因表現特徵。

近年來，全球免疫腫瘤治療市場經歷了顯著成長，規模已超過約2,000億美元，預計隨著新型查核點抑制劑、細胞療法和聯合治療的推出，該市場也將繼續擴張。這種成長推動了對預測性生物標記檢測的需求，這些檢測能夠識別最有可能從免疫療法中獲益的患者。

生物標記在腫瘤免疫學中的作用

生物標記在確定免疫治療策略中發揮核心作用。 PD-L1表現是應用最廣泛的生物標記之一，通常採用免疫組織化學（IHC）檢測進行評估。 PD-L1檢測用於確定非小細胞肺癌、黑色素瘤、膀胱癌和頭頸合格等癌症患者查核點檢查點抑制劑治療。

其他重要的生物標記包括腫瘤突變負荷（TMB）、微衛星不穩定性（MSI）、錯配修復缺陷（dMMR）以及表徵腫瘤微環境內免疫系統活性的基因表現。高腫瘤突變負荷和MSI-high狀態可能提示新抗原呈現增加，顯示對免疫查核點抑制劑的反應可能性較大。

新型生物標記包括免疫遺傳特徵、腫瘤浸潤淋巴細胞（TIL）密度測量以及透過液態生物檢體技術檢測到的循環生物標記。這些方法旨在提高預測準確性，超越單一生物標記檢測。

IO診斷中使用的技術

免疫腫瘤診斷市場涵蓋了多種分子和免疫學檢測技術。免疫組織化學（IHC）因其能夠檢測組織樣本中的蛋白質表現模式，仍是應用最廣泛的方法之一。 IHC檢測常用於測量PD-L1表現和其他免疫相關標記。

次世代定序(NGS) 技術能夠進行全面的基因組分析，並可同時檢測多種生物標記物，包括腫瘤突變負荷 (TMB)、微衛星不穩定性 (MSI) 和基因表現。 NGS 檢測組合既可用於伴隨診斷，也可用於更廣泛的腫瘤分析。

聚合酵素鏈鎖反應（PCR）技術在檢測特定基因突變和微衛星不穩定性方面繼續發揮至關重要的作用。數位病理學和影像分析技術正擴大被用於量化免疫細胞浸潤和生物標記表達模式。

液態生物檢體技術是免疫腫瘤學（IO）診斷市場的新興領域。這些檢測方法分析血液樣本中的循環腫瘤DNA和其他生物標記物，以便能夠以微創方式監測疾病進展和治療反應。

市場促進因素

多種因素正在推動腫瘤免疫診斷市場的成長。其中最重要的促進因素之一是免疫療法藥物研發管線的持續擴張。製藥公司正大力投資查核點抑制劑、細胞療法和聯合免疫療法，而這些療法都需要生物標記檢測來指南患者篩選。

此外，精準醫療方法的日益普及也推動了對眼內營養不良（IO）診斷的需求。臨床醫生擴大利用生物標記信息，根據每位患者的個別特徵制定治療策略。

基因測序技術和生物資訊學工具的進步提高了生物標記檢測的敏感度和特異性，促進了其在臨床環境中的更廣泛應用。

隨著聯合治療的應用日益廣泛，人們越來越需要更複雜的生物標記檢測策略，以便同時評估多種免疫途徑。

市場區隔

IO診斷市場可以按技術平台、癌症類型、最終用戶和地區進行細分。

從技術角度來看，免疫組織化學仍然被廣泛應用，但次世代定序是成長最快的領域之一，因為它能夠同時評估多個生物標記。

按癌症類型分類，肺癌已成為最大的癌症類別之一，這主要歸功於查核點抑制劑在非小細胞肺癌中的廣泛應用。其他重要的癌症類別包括黑色素瘤、膀胱癌、乳癌、大腸癌、頭頸癌。

最終用戶包括醫院檢查室、參考實驗室、學術研究機構和進行臨床試驗的製藥公司。

北美是最大的區域市場，這得益於其先進的醫療基礎設施和較高的免疫療法普及率。歐洲和亞太地區對腫瘤免疫學（IO）診斷檢測的需求也在增加。

競爭格局

免疫腫瘤診斷市場包括領先的體外診斷製造商、分子診斷公司和專注於生物標記發現的專業生物技術公司。

許多診斷公司與製藥公司合作，共同開發針對特定免疫療法藥物的伴隨診斷測試。策略合作十分常見，因為它們需要協調一致的臨床檢驗和監管核准。

各公司越來越注重開發能夠處理不同治療適應症中多種生物標記類型的多檢測平台。

隨著生物標記的解讀變得越來越複雜，數據分析和生物資訊能力正成為至關重要的競爭優勢。

未來展望

隨著免疫療法成為更多癌症類型和更早治療階段的標準療法，免疫腫瘤診斷市場預計將繼續擴張。

太空生物學、多重影像和基於人工智慧 (AI) 的生物標記分析等新興技術有可能提高預測準確性，並支持開發更個人化的治療策略。

液態生物檢體技術有可能透過對治療反應進行非侵入性監測來增加檢測次數。

總體而言，隨著免疫療法的不斷發展，腫瘤免疫學診斷有望繼續成為精準腫瘤學的關鍵組成部分，從而支持更有效的患者選擇和改善臨床結果。

目錄

第1章 市集指南

  • 情境分析
  • 高階主管和行銷負責人的指南
  • 投資分析師和管理顧問指南
  • 人工智慧的影響

第2章：引言與市場定義

  • 什麼是免疫腫瘤學診斷？
  • 免疫腫瘤學－未來的治療方法方向
  • 市場定義
  • 調查方法
  • 展望：醫療保健和體外診斷產業

第3章 免疫療法—免疫技術指南

  • 免疫系統
    • 先天免疫系統
    • 適應性免疫系統
    • 腫瘤免疫學－免疫監視系統
  • 免疫腫瘤學診斷
    • 查核點檢測
    • 細胞激素檢測
    • 基因組生殖細胞
    • 基因組腫瘤
    • 腫瘤微環境
    • 其他

第4章 行業概覽

  • 參與企業充滿活力的市場
    • 學術研究辦公室
    • 診斷測試開發人員
    • 測量儀器供應商
    • 化學品/試劑供應商
    • 病理檢測用品供應商
    • 獨立臨床實驗室
    • 國家/地區公共研究機構
    • 醫院檢查室
    • 醫師診所檢查室(POLS)
    • 審計機構
    • 認證機構

第5章 市場趨勢

  • 成長促進因素
  • 成長阻礙因素
  • 診斷技術發展

第6章：癌症免疫腫瘤學診斷的最新趨勢

第7章：主要免疫腫瘤公司概況

  • 10x Genomics, Inc.
  • Abbott Laboratories
  • AccuraGen Inc.
  • Adaptive Biotechnologies
  • Aethlon Medical
  • Agilent
  • Anchor Dx
  • ANGLE plc
  • ARUP Laboratories
  • AVIVA Systems Biology
  • Baylor Miraca Genetics Laboratories
  • Beckman Coulter Diagnostics（Danaher）
  • Becton, Dickinson and Company
  • Berkley Lights
  • BGI Genomics Co. Ltd
  • Bioarray Genetics
  • Biocartis
  • Biocept, Inc.
  • Biodesix Inc.
  • BioFluidica
  • BioGenex
  • BioIVT
  • Biolidics Ltd
  • bioMerieux Diagnostics
  • Bioneer Corporation
  • Bio-Rad Laboratories, Inc.
  • Bio-Reference Laboratories
  • Bio-Techne
  • Bioview
  • Bristol-Myers Squibb
  • Burning Rock
  • Cardiff Oncology
  • Caris Molecular Diagnostics
  • Castle Biosciences, Inc.
  • CellCarta
  • CellMax Life
  • Cepheid（Danaher）
  • Charles River Laboratories
  • Circulogene
  • Cizzle Biotech
  • Clearbridge Biomedics
  • Clinical Genomics
  • Cytolumina Technologies Corp.
  • Datar Cancer Genetics Limited
  • Diagnologix LLC
  • Diasorin SpA
  • Dxcover
  • Element Biosciences
  • Enzo Biochem
  • Epic Sciences
  • Epigenomics AG
  • Eurofins Scientific
  • Fabric Genomics
  • Fluxion Biosciences（Cell Microsystems）
  • Freenome
  • FUJIFILM Wako Diagnostics
  • Fujirebio
  • Fyr Diagnostics
  • GeneFirst Ltd.
  • Genetron Holdings
  • GenomOncology
  • GILUPI Nanomedizin
  • Guardant Health
  • HansaBiomed
  • HTG Molecular Diagnostics
  • iCellate
  • ICON PLC
  • Illumina
  • Incell Dx
  • Inivata
  • INOVIQ
  • Invitae Corporation
  • Invivogen
  • Invivoscribe
  • J&J Innovative Medicine
  • KEW
  • Lucence Health
  • Lunglife AI Inc
  • MDNA Life SCIENCES, Inc.
  • MDx Health
  • Menarini Silicon Biosystems
  • Mesa Laboratories, Inc.
  • Millipore Sigma
  • Miltenyi Biotec
  • miR Scientific
  • Myriad Genetics
  • Nanostring
  • NantHealth, Inc.
  • Natera
  • NeoGenomics
  • NGeneBio
  • Novogene
  • Oncimmune
  • Oncocyte
  • OncoDNA
  • Oncohost
  • Oxford Nanopore Technologies
  • PamGene
  • Panagene
  • Personalis
  • PGDx（Labcorp）
  • Precipio
  • PrecisionMed
  • Predicine
  • Predictive Oncology
  • Prenetics
  • Promega
  • Qiagen
  • QuidelOrtho
  • Rarecells SAS
  • RareCyte
  • Recursion Pharma
  • Revvity
  • Roche Diagnostics
  • Screencell
  • Sherlock Biosciences
  • Siemens Healthineers
  • simfo GmbH
  • Singlera Genomics Inc.
  • Singular Genomics
  • Singulomics
  • SkylineDx
  • Standard BioTools
  • Stilla Technologies
  • Sysmex Inostics
  • Tempus Labs, Inc.
  • Thermo Fisher Scientific
  • Todos Medical
  • Ultima Genomics
  • Veracyte
  • VolitionRX
  • Vortex Biosciences

第8章：全球免疫腫瘤診斷市場

  • 全球市場概覽（按國家/地區分類）
  • 全球市場按檢測類型分類 - 概述
  • 全球市場概覽（依技術分類）
  • 按客戶群分類的全球市場概覽

第9章 全球免疫腫瘤診斷市場－依應用領域分類

  • 查核點
  • 細胞激素
  • 生殖細胞基因
  • 遺傳性腫瘤
  • 腫瘤微環境
  • 其他

第10章：全球免疫腫瘤診斷市場－依技術分類

  • NGS
  • PCR
  • FISH/IHC
  • Chem/IA
  • 其他

第11章 全球免疫腫瘤診斷市場－依客戶分類

  • 製藥
  • 診所
  • 其他

第12章附錄

表格一覽

圖表清單

簡介目錄
Product Code: CANIODx 426

Market Overview:

Market Size 2025: USD $6.22B Market Size 2030: USD $11.1B CAGR: 12.3%

Immuno-oncology (IO) diagnostics are in vitro diagnostic tests used to identify biomarkers that predict patient response to immunotherapies. These therapies stimulate or restore the immune system's ability to recognize and destroy cancer cells and have become one of the most important advances in oncology over the past decade. As immunotherapies increasingly become standard treatment options across multiple tumor types, diagnostic tests that guide patient selection have become critical components of clinical decision-making.

The IO diagnostics market has developed in parallel with the rapid expansion of immunotherapy drug classes, including immune checkpoint inhibitors, CAR-T cell therapies, bispecific antibodies, and therapeutic cancer vaccines. Unlike traditional targeted therapies that focus on specific genetic mutations, immunotherapies rely on complex interactions between tumors and the immune system. As a result, IO diagnostics often require evaluation of multiple biological parameters including protein expression, immune cell infiltration, tumor mutational burden, and gene expression signatures.

The global immuno-oncology therapeutics market has demonstrated substantial growth, exceeding approximately USD 200 billion in recent years and projected to continue expanding as additional checkpoint inhibitors, cell therapies, and combination therapies are introduced. This growth is driving demand for predictive biomarker testing capable of identifying patients most likely to benefit from immune-based treatments.

Role of Biomarkers in Immuno-Oncology

Biomarkers play a central role in guiding immunotherapy treatment decisions. One of the most widely used biomarkers is PD-L1 expression, which is commonly assessed using immunohistochemistry (IHC) assays. PD-L1 testing is used to determine eligibility for checkpoint inhibitor therapies targeting PD-1 or PD-L1 pathways in cancers such as non-small cell lung cancer, melanoma, bladder cancer, and head and neck cancer.

Other important biomarkers include tumor mutational burden (TMB), microsatellite instability (MSI), mismatch repair deficiency (dMMR), and gene expression profiles that characterize immune system activity within the tumor microenvironment. High tumor mutational burden or MSI-high status may indicate increased likelihood of response to immune checkpoint inhibitors due to greater neoantigen presentation.

Emerging biomarkers include immune gene signatures, tumor-infiltrating lymphocyte (TIL) density measurements, and circulating biomarkers detected through liquid biopsy technologies. These approaches aim to improve predictive accuracy beyond single biomarker testing.

Technologies Used in IO Diagnostics

The IO diagnostics market incorporates a range of molecular and immunological testing technologies. Immunohistochemistry remains one of the most widely used methods due to its ability to detect protein expression patterns within tissue samples. IHC assays are commonly used to measure PD-L1 expression and other immune-related markers.

Next-generation sequencing (NGS) technologies enable comprehensive genomic profiling, allowing simultaneous detection of multiple biomarkers including TMB, MSI, and gene expression signatures. NGS panels can support both companion diagnostics and broader tumor profiling approaches.

Polymerase chain reaction (PCR) technologies continue to play an important role in detecting specific genetic alterations and microsatellite instability. Digital pathology and image analysis technologies are increasingly used to quantify immune cell infiltration and biomarker expression patterns.

Liquid biopsy technologies represent an emerging segment of the IO diagnostics market. These tests analyze circulating tumor DNA or other biomarkers in blood samples, enabling less invasive monitoring of disease progression and treatment response.

Market Drivers

Several factors are driving growth in the immuno-oncology diagnostics market. One of the most significant drivers is the continued expansion of immunotherapy drug pipelines. Pharmaceutical companies are investing heavily in checkpoint inhibitors, cell therapies, and combination immunotherapies that require biomarker testing to guide patient selection.

Increasing adoption of precision medicine approaches is also supporting demand for IO diagnostics. Clinicians are increasingly using biomarker information to tailor treatment decisions based on individual patient characteristics.

Advances in genomic sequencing technologies and bioinformatics tools have improved the sensitivity and specificity of biomarker detection, supporting broader clinical adoption.

The growing use of combination therapies is also increasing the need for more complex biomarker testing strategies capable of evaluating multiple immune pathways simultaneously.

Market Segmentation

The IO diagnostics market can be segmented by technology platform, cancer type, end user, and geographic region.

By technology, immunohistochemistry remains widely used, while next-generation sequencing represents one of the fastest-growing segments due to its ability to evaluate multiple biomarkers simultaneously.

By cancer type, lung cancer represents one of the largest segments due to widespread use of checkpoint inhibitors in non-small cell lung cancer. Other important segments include melanoma, bladder cancer, breast cancer, colorectal cancer, and head and neck cancer.

End users include hospital laboratories, reference laboratories, academic research centers, and pharmaceutical companies conducting clinical trials.

North America represents the largest geographic market due to advanced healthcare infrastructure and high adoption of immunotherapy treatments. Europe and Asia-Pacific are also experiencing increasing demand for IO diagnostic testing.

Competitive Landscape

The immuno-oncology diagnostics market includes large in vitro diagnostics companies, molecular diagnostics firms, and specialized biotechnology companies focused on biomarker discovery.

Many diagnostic developers partner with pharmaceutical companies to co-develop companion diagnostic tests aligned with specific immunotherapy drugs. Strategic collaborations are common due to the need for coordinated clinical validation and regulatory approval.

Companies are increasingly focused on developing multiplex testing platforms capable of supporting multiple biomarker types across therapeutic indications.

Data analytics and bioinformatics capabilities are becoming important competitive differentiators as biomarker interpretation becomes more complex.

Future Outlook

The immuno-oncology diagnostics market is expected to continue expanding as immunotherapies become standard treatments across additional cancer types and earlier lines of therapy.

Emerging technologies such as spatial biology, multiplex imaging, and artificial intelligence-based biomarker analysis may improve predictive accuracy and support development of more personalized treatment strategies.

Liquid biopsy technologies may expand testing volumes by enabling non-invasive monitoring of treatment response.

Overall, IO diagnostics are expected to remain a critical component of precision oncology, supporting more effective patient selection and improved clinical outcomes as immunotherapy continues to evolve.

Table of Contents

1 Market Guides

  • 1.1 Situation Analysis
    • 1.1.1 Strategic Importance of Biomarkers in Immuno-Oncology
    • 1.1.2 Scientific Complexity and Biomarker Validation Challenges
    • 1.1.3 Regulatory Complexity and Co-development Risk
    • 1.1.4 Technology Evolution and Platform Competition
    • 1.1.5 Reimbursement and Economic Value Considerations
    • 1.1.6 Dependence on Immunotherapy Drug Pipelines
    • 1.1.7 Competitive Landscape and Industry Structure
    • 1.1.8 Outlook and Strategic Implications
  • 1.2 Guide for Executives and Marketing Staff
  • 1.3 Guide for Investment Analysts and Management Consultants
  • 1.4 Impact of Artificial Intelligence

2 Introduction and Market Definition

  • 2.1 What are Immuno-Oncology Diagnostics?
  • 2.2 Immuno-oncology - the looming cure
    • 2.2.1 Immuno-oncology Diagnostics Takes a Leading Role
  • 2.3 Market Definition
    • 2.3.1 Market Size
    • 2.3.2 Currency
    • 2.3.3 Years
  • 2.4 Methodology
    • 2.4.1 Methodology
    • 2.4.2 Sources
    • 2.4.3 Authors
  • 2.5 Perspective: Healthcare and the IVD Industry
    • 2.5.1 Global Healthcare Spending
    • 2.5.2 Spending on Diagnostics
    • 2.5.3 Important Role of Insurance for Diagnostics

3 Immunotherapy - Guide to Immune Technologies

  • 3.1 The Immune System
    • 3.1.1 Innate immune system
      • 3.1.1.1 Surface barriers
      • 3.1.1.2 Inflammation
      • 3.1.1.3 Complement system
      • 3.1.1.4 Cellular barriers
      • 3.1.1.5 Natural killer cells
    • 3.1.2 Adaptive immune system
      • 3.1.2.1 Lymphocytes
      • 3.1.2.2 Killer T cells
      • 3.1.2.3 Helper T cells
      • 3.1.2.4 Gamma delta T cells
      • 3.1.2.5 B lymphocytes and antibodies
    • 3.1.3 Tumor immunology - the immune surveillance system
  • 3.2 Immuno Oncology Diagnostics
    • 3.2.1 Checkpoint Assays
      • 3.2.1.1 Outlook for Checkpoint Assays
    • 3.2.2 Cytokine Assays
      • 3.2.2.1 Outlook for Cytokine Assays
    • 3.2.3 Genomic Germline
      • 3.2.3.1 Outlook for Genomic Germline
    • 3.2.4 Genomic Tumour
      • 3.2.4.1 Outlook for Genomic Tumour
    • 3.2.5 Tumor Microenviroment
      • 3.2.5.1 Outlook for Tumor Microenvironment
    • 3.2.6 Others
      • 3.2.6.1 Outlook for Other Diagnostics

4 Industry Overview

  • 4.1 Players in a Dynamic Market
    • 4.1.1 Academic Research Lab
    • 4.1.2 Diagnostic Test Developer
    • 4.1.3 Instrumentation Supplier
    • 4.1.4 Chemical/Reagent Supplier
    • 4.1.5 Pathology Supplier
    • 4.1.6 Independent Clinical Laboratory
    • 4.1.7 Public National/regional Laboratory
    • 4.1.8 Hospital Laboratory
    • 4.1.9 Physicians Office Lab (POLS)
    • 4.1.10 Audit Body
    • 4.1.11 Certification Body

5 Market Trends

  • 5.1 Factors Driving Growth
    • 5.1.1 Outcome potential
    • 5.1.2 Companion Diagnostics
    • 5.1.3 Funding
    • 5.1.4 Technology Environment
    • 5.1.5 Target Solutions
  • 5.2 Factors Limiting Growth
    • 5.2.1 Complex Role of Diagnostics
    • 5.2.2 Clinical Trials Role
    • 5.2.3 Protocols
  • 5.3 Diagnostic Technology Development
    • 5.3.1 Combinations - Issues and Complexity
    • 5.3.2 Shifting Role of Diagnostics
    • 5.3.3 Multiplexing and Foundation One
    • 5.3.4 The Disruption Dynamic
    • 5.3.5 The Race for Biomarkers
    • 5.3.6 The Next Five Years

6 Cancer Immuno-Oncology Diagnostics Recent Developments

  • 6.1 Recent Developments - Importance and How to Use This Section
    • 6.1.1 Importance of These Developments
    • 6.1.2 How to Use This Section
  • 6.2 Personalis Outlook Positive
  • 6.3 Agilent Technologies Expands Certification for PD-L1 CDx
  • 6.4 Foundation Medicine, Sumitomo Pharma to Develop CDx
  • 6.5 Erisyon to Develop Diagnostic for Immuno-Oncology
  • 6.6 Caris Life Sciences Expands CDx
  • 6.7 FDA approves Illumina cancer biomarker test
  • 6.8 Tempus Expands Immuno-Oncology Portfolio with AI
  • 6.9 Foundation Medicine, Repare to Partner on CDx for Lunresertib
  • 6.10 Thermo Fisher and Bayer to Develop CDx for Cancer Therapies
  • 6.11 ClearNote Health Expands Into Immunotherapy Monitoring
  • 6.12 Foundation Medicine to Collaborate on CDx for Lung Cancer
  • 6.13 Qiagen and Myriad Genetics Partner to Develop Cancer CDx
  • 6.14 Lung Cancer Data Heralds Shift for Hummingbird Dx
  • 6.15 PamGene Awarded Euro 7.5M for Immunotherapy Test
  • 6.16 Freenome Acquires Oncimmune
  • 6.17 Guardant Health Gets Coverage for Liquid Biopsy Treatment Response Test
  • 6.18 BostonGene to Develop Sarcoma-Specific Liquid Biopsy
  • 6.19 Exact Sciences OncoExTra Therapy Selection Test
  • 6.20 Integrated DNA Technologies Buys NGS Research Assays
  • 6.21 Navignostics Using Single-Cell Spatial Proteomics
  • 6.22 New Reference Samples for NGS-Based Cancer Tests
  • 6.23 Spatial Proteomics Panel for Immuno-Oncology
  • 6.24 dMMR, MSI Assays for Immunotherapy Patient Selection
  • 6.25 OncoHost Expands Prophet Platform Research
  • 6.26 Protein-Based Liquid Biopsy Panel Assesses TME

7 Profiles of Key Immuno-oncology Companies

  • 7.1 10x Genomics, Inc.
  • 7.2 Abbott Laboratories
  • 7.3 AccuraGen Inc.
  • 7.4 Adaptive Biotechnologies
  • 7.5 Aethlon Medical
  • 7.6 Agilent
  • 7.7 Anchor Dx
  • 7.8 ANGLE plc
  • 7.9 ARUP Laboratories
  • 7.10 AVIVA Systems Biology
  • 7.11 Baylor Miraca Genetics Laboratories
  • 7.12 Beckman Coulter Diagnostics (Danaher)
  • 7.13 Becton, Dickinson and Company
  • 7.14 Berkley Lights
  • 7.15 BGI Genomics Co. Ltd
  • 7.16 Bioarray Genetics
  • 7.17 Biocartis
  • 7.18 Biocept, Inc.
  • 7.19 Biodesix Inc.
  • 7.20 BioFluidica
  • 7.21 BioGenex
  • 7.22 BioIVT
  • 7.23 Biolidics Ltd
  • 7.24 bioMerieux Diagnostics
  • 7.25 Bioneer Corporation
  • 7.26 Bio-Rad Laboratories, Inc.
  • 7.27 Bio-Reference Laboratories
  • 7.28 Bio-Techne
  • 7.29 Bioview
  • 7.30 Bristol-Myers Squibb
  • 7.31 Burning Rock
  • 7.32 Cardiff Oncology
  • 7.33 Caris Molecular Diagnostics
  • 7.34 Castle Biosciences, Inc.
  • 7.35 CellCarta
  • 7.36 CellMax Life
  • 7.37 Cepheid (Danaher)
  • 7.38 Charles River Laboratories
  • 7.39 Circulogene
  • 7.40 Cizzle Biotech
  • 7.41 Clearbridge Biomedics
  • 7.42 Clinical Genomics
  • 7.43 Cytolumina Technologies Corp.
  • 7.44 Datar Cancer Genetics Limited
  • 7.45 Diagnologix LLC
  • 7.46 Diasorin S.p.A.
  • 7.47 Dxcover
  • 7.48 Element Biosciences
  • 7.49 Enzo Biochem
  • 7.50 Epic Sciences
  • 7.51 Epigenomics AG
  • 7.52 Eurofins Scientific
  • 7.53 Fabric Genomics
  • 7.54 Fluxion Biosciences (Cell Microsystems)
  • 7.55 Freenome
  • 7.56 FUJIFILM Wako Diagnostics
  • 7.57 Fujirebio
  • 7.58 Fyr Diagnostics
  • 7.59 GeneFirst Ltd.
  • 7.60 Genetron Holdings
  • 7.61 GenomOncology
  • 7.62 GILUPI Nanomedizin
  • 7.63 Guardant Health
  • 7.64 HansaBiomed
  • 7.65 HTG Molecular Diagnostics
  • 7.66 iCellate
  • 7.67 ICON PLC
  • 7.68 Illumina
  • 7.69 Incell Dx
  • 7.70 Inivata
  • 7.71 INOVIQ
  • 7.72 Invitae Corporation
  • 7.73 Invivogen
  • 7.74 Invivoscribe
  • 7.75 J&J Innovative Medicine
  • 7.76 KEW
  • 7.77 Lucence Health
  • 7.78 Lunglife AI Inc
  • 7.79 MDNA Life SCIENCES, Inc.
  • 7.80 MDx Health
  • 7.81 Menarini Silicon Biosystems
  • 7.82 Mesa Laboratories, Inc.
  • 7.83 Millipore Sigma
  • 7.84 Miltenyi Biotec
  • 7.85 miR Scientific
  • 7.86 Myriad Genetics
  • 7.87 Nanostring
  • 7.88 NantHealth, Inc.
  • 7.89 Natera
  • 7.90 NeoGenomics
  • 7.91 NGeneBio
  • 7.92 Novogene
  • 7.93 Oncimmune
  • 7.94 Oncocyte
  • 7.95 OncoDNA
  • 7.96 Oncohost
  • 7.97 Oxford Nanopore Technologies
  • 7.98 PamGene
  • 7.99 Panagene
  • 7.100 Personalis
  • 7.101 PGDx (Labcorp)
  • 7.102 Precipio
  • 7.103 PrecisionMed
  • 7.104 Predicine
  • 7.105 Predictive Oncology
  • 7.106 Prenetics
  • 7.107 Promega
  • 7.108 Qiagen
  • 7.109 QuidelOrtho
  • 7.110 Rarecells SAS
  • 7.111 RareCyte
  • 7.112 Recursion Pharma
  • 7.113 Revvity
  • 7.114 Roche Diagnostics
  • 7.115 Screencell
  • 7.116 Sherlock Biosciences
  • 7.117 Siemens Healthineers
  • 7.118 simfo GmbH
  • 7.119 Singlera Genomics Inc.
  • 7.120 Singular Genomics
  • 7.121 Singulomics
  • 7.122 SkylineDx
  • 7.123 Standard BioTools
  • 7.124 Stilla Technologies
  • 7.125 Sysmex Inostics
  • 7.126 Tempus Labs, Inc.
  • 7.127 Thermo Fisher Scientific
  • 7.128 Todos Medical
  • 7.129 Ultima Genomics
  • 7.130 Veracyte
  • 7.131 VolitionRX
  • 7.132 Vortex Biosciences

8 The Global Market for Immuno-Oncology Diagnostics

  • 8.1 Global Market Overview by Country
    • 8.1.1 Table - Global Market by Country
    • 8.1.2 Chart - Global Market by Country
  • 8.2 Global Market by Assay Type - Overview
    • 8.2.1 Table - Global Market by Assay Type
    • 8.2.2 Chart - Global Market by Assay Type - Base/Final Year Comparison
    • 8.2.3 Chart - Global Market by Assay Type - Base Year
    • 8.2.4 Chart - Global Market by Assay Type - End Year
    • 8.2.5 Chart - Global Market by Assay Type - Share by Year
    • 8.2.6 Chart - Global Market by Assay Type - Segments Growth
  • 8.3 Global Market by Technology - Overview
    • 8.3.1 Table - Global Market by Technology
    • 8.3.2 Chart - Global Market by Technology - Base/Final Year Comparison
    • 8.3.3 Chart - Global Market by Technology - Base Year
    • 8.3.4 Chart - Global Market by Technology - End Year
    • 8.3.5 Chart - Global Market by Technology - Share by Year
    • 8.3.6 Chart - Global Market by Technology - Segments Growth
  • 8.4 Global Market by Customer - Overview
    • 8.4.1 Table - Global Market by Customer
    • 8.4.2 Chart - Global Market by Customer - Base/Final Year Comparison
    • 8.4.3 Chart - Global Market by Customer - Base Year
    • 8.4.4 Chart - Global Market by Customer - End Year
    • 8.4.5 Chart - Global Market by Customer - Share by Year
    • 8.4.6 Chart - Global Market by Customer - Segments Growth

9 Global Immuno-Oncology Diagnostic Markets - By Application

  • 9.1 Checkpoint
    • 9.1.1 Table Checkpoint - by Country
    • 9.1.2 Chart - Checkpoint Growth
  • 9.2 Cytokine
    • 9.2.1 Table Cytokine - by Country
    • 9.2.2 Chart - Cytokine Growth
  • 9.3 Germline Genetic
    • 9.3.1 Table Germline Genetic - by Country
    • 9.3.2 Chart - Germline Genetic Growth
  • 9.4 Genetic Tumor
    • 9.4.1 Table Genetic Tumor - by Country
    • 9.4.2 Chart - Genetic Tumor Growth
  • 9.5 Tumor Microenvironment
    • 9.5.1 Table Tumor Microenvironment - by Country
    • 9.5.2 Chart - Tumor Microenvironment Growth
  • 9.6 Other
    • 9.6.1 Table Other - by Country
    • 9.6.2 Chart - Other Growth

10 Global Immuno-Oncology Diagnostic Markets - By Technology

  • 10.1 NGS
    • 10.1.1 Table NGS - by Country
    • 10.1.2 Chart - NGS Growth
  • 10.2 PCR
    • 10.2.1 Table PCR - by Country
    • 10.2.2 Chart - PCR Growth
  • 10.3 Fish/IHC
    • 10.3.1 Table Fish/IHC - by Country
    • 10.3.2 Chart - Fish/IHC Growth
  • 10.4 Chem/IA
    • 10.4.1 Table Chem/IA - by Country
    • 10.4.2 Chart - Chem/IA Growth
  • 10.5 Other Technology
    • 10.5.1 Table Other Technology - by Country
    • 10.5.2 Chart - Other Technology Growth

11 Global Immuno-Oncology Diagnostic Markets - By Customer

  • 11.1 Pharma
    • 11.1.1 Table Pharma - by Country
    • 11.1.2 Chart - Pharma Growth
  • 11.2 Clinic
    • 11.2.1 Table Clinic - by Country
    • 11.2.2 Chart - Clinic Growth
  • 11.3 Other Customer Genetic
    • 11.3.1 Table Other Customer - by Country
    • 11.3.2 Chart - Other Customer Growth

12 Appendices

  • 12.1 Prevalence of Cancer Treatments
  • 12.2 Growth of Approved IVD Test Menu
  • 12.3 Growth of Approved Average IVD Test Fee
  • 12.4 The Most Used IVD Assays
  • 12.5 The Highest Grossing Assays
  • 12.6 Laboratory Fees Schedule

Table of Tables

  • Table 1 List of Cancers by Mortality
  • Table 2 Overview of Innate and Adaptive Immunity
  • Table 3 FDA Approved Monoclonal Antibodies in Cancer treatment
  • Table 4 FDA Approved Companion diagnostics in Cancer treatment
  • Table 5 Market Players by Type
  • Table 6 Five Factors Driving Growth
  • Table 7 Three Factors Limiting Growth
  • Table 8 - Global Market by Region
  • Table 9 Global Market by Assay Type
  • Table 10 Global Market by Technology
  • Table 11 Global Market by Customer
  • Table 12 Checkpoint by Country
  • Table 13 Cytokine by Country
  • Table 14 Germline Genetic by Country
  • Table 15 Genetic Tumor by Country
  • Table 16 Tumor Microenvironment by Country
  • Table 17 Other by Country
  • Table 18 NGS by Country
  • Table 19 PCR by Country
  • Table 20 Fish/IHC by Country
  • Table 21 Chem/IA by Country
  • Table 22 Other Technology by Country
  • Table 23 Pharma by Country
  • Table 24 Clinic by Country
  • Table 25 Other Customer by Country
  • Table 26 The Most Common Assays
  • Table 27 Largest Revenue Assays
  • Table 28 Clinical Lab Fee Schedule

Table of Figures

  • Figure 1 Cancer Death Rates - USA, CDC
  • Figure 2 Global healthcare Spending
  • Figure 3 The Lab Test Pie
  • Figure 4 Helper T Cell Roles
  • Figure 5 Antibody Diagram
  • Figure 6 Macrophages attack a Cancer Cell
  • Figure 7 The Tumour Micro Environment
  • Figure 8 The Road to Diagnostics
  • Figure 9 Comparing IO Diagnostic and Traditional Testing
  • Figure 10 Growth rates of IO DiagnosticTechnologies
  • Figure 11 Global Market Density Chart
  • Figure 12 Global Market by Assay Type - Base vs. Final
  • Figure 13 Global Market by Assay Type Base Year
  • Figure 14 Global Market by Assay Type End Year
  • Figure 15 Assay Type Share by Year
  • Figure 16 Assay Type Segments Growth
  • Figure 17 Global Market by Technology - Base vs. Final
  • Figure 18 Global Market by Technology Base Year
  • Figure 19 Global Market by Technology End Year
  • Figure 20 Technology Share by Year
  • Figure 21 Technology Segments Growth
  • Figure 22 Global Market by Customer - Base vs. Final
  • Figure 23 Global Market by Customer Base Year
  • Figure 24 Global Market by Customer End Year
  • Figure 25 Customer Share by Year
  • Figure 26 Customer Segments Growth
  • Figure 27 Checkpoint Growth
  • Figure 28 Cytokine Growth
  • Figure 29 Germline Genetic Growth
  • Figure 30 Genetic Tumor Growth
  • Figure 31 Tumor Microenvironment Growth
  • Figure 32 Other Growth
  • Figure 33 NGS Growth
  • Figure 34 PCR Growth
  • Figure 35 Fish/IHC Growth
  • Figure 36 Chem/IA Growth
  • Figure 37 Other Technology Growth
  • Figure 38 Pharma Growth
  • Figure 39 Clinic Growth
  • Figure 40 Other Customer Growth
  • Figure 41 Prevalence of Cancer Treatments
  • Figure 42 IVD Test Menu Growth
  • Figure 43 IVD Test Average Fees - A Ten Year View